Bioline RX Ltd Sponsored ADR (BLRX) Price & Analysis

Compare

2,534 Followers

BLRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.30 - $32.24

Previous CloseN/A

Volume8.80M

Average Volume (3M)38.39K

Market Cap

$15.89M

Enterprise Value$13.66M

Total Cash (Recent Filing)$19.56M

Total Debt (Recent Filing)$15.04M

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Dec 01, 2025

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding4,262,685

10 Day Avg. Volume46,380

30 Day Avg. Volume38,387

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.86

Enterprise Value/Revenue0.47

Enterprise Value/Gross Profit0.69

Enterprise Value/Ebitda3.49

Forecast

1Y Price Target

$14.00

Price Target Upside277.36% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsFavorable results from the use of motixafortide in a therapeutic combination in pancreatic cancer increase the likelihood that BLRX will find a development partner.

Financial StabilityAPHEXDA will provide a steady stream of royalties that support earlier stage development of assets expected to be in-licensed, most likely in oncology and/or rare disease spaces.

Bears Say

Adverse EventsThe most common Grade ≥ III adverse events in the trial were anemia and rash, which could impact patient outcomes.

Financial PerformanceBioLineRx announced 2Q25 financial results, posting EPS of ($1.00) vs. the estimate of ($0.35), primarily due to warrant accounting adjustments.

Bioline RX Ltd Sponsored ADR News

BioLineRx reports Q2 EPS 0c vs. 0c last year

Reports Q2 revenue $300K, consensus $661.33K. As of June 30, 2025, the company had cash, cash equivalents, and...

3d ago

BLRX

Options Volatility and Implied Earnings Moves Today, August 14, 2025

Today, several major companies are expected to report earnings: Applied Materials (AMAT), Bioline RX Ltd Sponsored ADR (BLRX),...

3d ago

BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating

JonesTrading analyst Justin Walsh has reiterated their bullish stance on BLRX stock, giving a Buy rating yesterday. Justin...

1d ago

BLRX

BioLineRx Ltd. Reports Q2 2025 Financial Results

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has released its Q2 earnings. Here is a breakdown of...

2d ago

BLRX

BioLineRx: Promising Financial Position and Strategic Initiatives Drive Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Bioline RX Ltd Sponsored ADR, retaining the...

2d ago

BLRX

BioLineRx Reports Q2 2025 Financials and Strategic Updates

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an announcement. On August 14, 2025, BioLineRx Ltd....

3d ago

BLRX

BioLineRx Ltd. Approves Key Proposals at Annual Meeting

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has provided an announcement. On June 29, 2025, BioLineRx Ltd....

2M ago

BLRX

Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research...

2M ago

BLRX

BioLineRx upgraded to Buy from Hold at JonesResearch

JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot...

3M ago

BLRX

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an update. BioLineRx Ltd. announced promising new data...

3M ago

BLRX

BioLineRx announces new data from Phase 2 combination trial of motixafortide

BioLineRx (BLRX) announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized...

3M ago

BLRX

BioLineRx ADR: Positive Earnings Call Highlights and Challenges

Bioline RX Ltd Sponsored ADR (($BLRX)) has held its Q1 earnings call. Read on for the main highlights...

3M ago

BLRX

BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Bioline RX Ltd...

3M ago

BLRX

Morning Movers: Informatica and Salesforce gain after $8B transaction

Stock market futures are rallying as investor sentiment improves following a delay in U.S. tariffs on European Union...

3M ago

AZO

BNS

BLRX FAQ

What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?

Bioline RX Ltd Sponsored ADR lowest stock price was $2.30 and its highest was $32.24 in the past 12 months.

What is Bioline RX Ltd Sponsored ADR’s market cap?

Bioline RX Ltd Sponsored ADR’s market cap is $15.89M.

When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?

Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Dec 01, 2025 which is in 106 days.

How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?

Bioline RX Ltd Sponsored ADR released its earnings results on Aug 14, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.353 by $0.353.

Is Bioline RX Ltd Sponsored ADR overvalued?

According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bioline RX Ltd Sponsored ADR pay dividends?

Bioline RX Ltd Sponsored ADR does not currently pay dividends.

What is Bioline RX Ltd Sponsored ADR’s EPS estimate?

Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.36.

How many shares outstanding does Bioline RX Ltd Sponsored ADR have?

Bioline RX Ltd Sponsored ADR has 4,262,685 shares outstanding.

What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?

Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$0.353. Following the earnings report the stock price went down -4.315%.

Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?

Currently, no hedge funds are holding shares in BLRX

Company Description

Bioline RX Ltd Sponsored ADR

Bioline RX Ltd Sponsored ADR (BLRX) is a biotechnology company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary technologies to create novel drug candidates. Bioline RX is engaged in the research, development, and commercialization of its product pipeline, which includes therapeutics targeting various cancer indications and immune-related disorders.

Bioline RX Ltd Sponsored ADR (BLRX) Earnings & Revenues

Historic Earnings Reports

BLRX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive outlook with significant achievements in licensing agreements, financial efficiency, and promising clinical trial results in pancreatic cancer. However, there were challenges in revenue generation due to the transition of APHEXDA sales and ongoing efforts to acquire new assets without a definitive outcome yet.View all BLRX earnings summaries

BLRX Stock 12 Month Forecast

Average Price Target

$14.00

▲(277.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","54":"$54","14.25":"$14.25","27.5":"$27.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,14.25,27.5,40.75,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.87,5.572307692307692,7.274615384615385,8.976923076923077,10.67923076923077,12.381538461538462,14.083846153846153,15.786153846153848,17.48846153846154,19.19076923076923,20.893076923076922,22.595384615384617,24.29769230769231,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.87,4.649230769230769,5.428461538461539,6.207692307692308,6.986923076923077,7.766153846153846,8.545384615384616,9.324615384615385,10.103846153846153,10.883076923076922,11.662307692307692,12.44153846153846,13.220769230769232,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.87,3.88,3.89,3.9,3.91,3.92,3.93,3.94,3.95,3.96,3.97,3.98,3.99,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.41,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.82,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >